Skip to main content
SpringerLink
Log in

Six treatments get accepted by the SMC

  • Unknown
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Scottish Medicines Consortium. SMC advice: alemtuzumab (Lemtrada); beclometasone dipropionate (Fostair); botulinum toxin type A (Botox); certolizumab pegol (Cimzia); dapagliflozin (Forxiga); pomalidomide (Imnovid); rituximab subcutaneous (Mabthera). Internet Document : 7 Jul 2014. Available from: URL: http://www.scottishmedicines.org.uk

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Six treatments get accepted by the SMC. PharmacoEcon Outcomes News 707, 11 (2014). https://doi.org/10.1007/s40274-014-1407-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-014-1407-9

Search

Navigation